Fluticasone furoate/umeclidinium bromide/vilanterol

< Fluticasone furoate < umeclidinium bromide

Fluticasone furoate/umeclidinium bromide/vilanterol
Combination of
Fluticasone furoateCorticosteroid
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Clinical data
Trade namesTrelegy Ellipta, Elebrato Ellipta, Temybric Ellipta
Other namesFF/UMEC/VI
AHFS/Drugs.comMonograph
MedlinePlusa618017
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
KEGG

Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The medications work in different ways: fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta-agonist (LABA).

In 2022, it was the 144th most commonly prescribed medication in the United States, with more than 3 million prescriptions.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.